Lantern

Home → Volume 1/ Issue 3 → Medical Treatment → Anti-tumor necrosis factor therapy

F. Medical Treatment

    Anti-tumor necrosis factor therapy

    50. Anti-tumor necrosis factor " therapy leads to improvement of enthesitis and synovitis in children with enthesitis-related arthritis
        SML Tse, A Doria, P Babyn, C. Boros, S Parker, BM Feldman, RM Laxer

    51 Therapeutic use of etanercept in polyarticular course juvenile rheumatoid arthritis over a 3-4 year period
        TL Moore, U Daud, DA Kietz, PH Pepmueller

    52. Response to etanercept in systemic juvenile idiopathic arthritis
        Y Kimura, P Pinho, G Higgins, D Hummell, I Szer, M Henrickson, D Goldsmith, C Wallace, D Rothman, J Hollister, S Li.

    53. Clinical responses to etanercept in systemic arthritis measure by "core set" outcome variables
        KM Bailey, CJ Ryder, TR Southwood

    49. Etanercept/methotrexate registry in juvenile rheumatoid arthritis
        EH Giannini, DJ Lovell, TM Sherrard, NT Ilowite, AA Reiff, the PRCSG

    54. Improved height development in children with juvenile idiopathic arthritis treated with etanercept
        M Rygg, R Svendsrud, NT Songstad, EB Nordal

    55. What does CHAQ tell us about effects of etanercept in children with juvenile idiopathic arthritis?
        K Bergren, A C Eliasson, S Hagelberg

    56. Niacin-like effect associated with infliximab therapy in systemic JRA
        G McIlvain-Simpson, ML Becker, CD Rose

    57. The beneficial effect of infliximab in amyloidosis secondary to JIA:  A case with a 20 month follow-up
        H Ozdogan, F Gogus, S Masatlioglu, D Cevirgen

    58. Disseminated herpes simplex infection precipitating macrophage activation syndrome in a child with systemic juvenile idiopathic arthritis undergoing therapy with infliximab
        JM Skripak, GL Rodgers, C Martucci, DP Goldsmith

    59. Treatment of juvenile onset idiopathic arthritis with infliximab
         H Ozdogan, F Gogus, S Masatlioglu, D Cevirgen